Melanotan 2 research, brain-first.

Before the details

Melanotan 2 research splits into two streams. The famous one is skin: the peptide darkens it without sun. The deeper one is the brain. The same receptors that drive pigment also sit in the brain's appetite and reward circuits, and that is where the most striking recent work lives.

The short list of what studies measured: in mice, the peptide cut food intake and food-seeking when injected straight into a reward center ^[5]. In rats, it switched on oxytocin neurons ^[8]. In a small human pilot, it darkened skin and produced erections ^[1]. And case reports flag real harms — darkened moles, kidney injury, priapism. The terms below are glossed in plain words on first use. The full bibliography is the Melanotan 2 references list.

The neuro-behavioral findings

Start in the brain, because that is this site's lens.

Appetite, at the reward center. In male C57BL/6J mice, bilateral microinjection of Melanotan II into the nucleus accumbens (a deep-brain hub for reward and motivation) at 0.1-1 nmol per side cut food consumption in both home-cage and lever-pressing tests, and cut the effort animals would put into getting food — without conditioned taste aversion and without changing metabolic rate ^[5]. Translation: the peptide dialed down food motivation at the level of wanting, not by making the animals queasy.

Oxytocin and social behavior. Intravenous Melanotan II in rats induced Fos (a marker of recently active neurons) in the supraoptic and paraventricular nuclei of the hypothalamus and raised the activity and secretion of oxytocin neurons — the cells behind the "bonding" hormone ^[8]. A 2024 study tightened the loop: melanocortin agonism selectively activated the nucleus accumbens in a social context, and the effect was oxytocin-dependent ^[9].

Mood and stress. A 2024 rat study of chronic unpredictable stress reported antidepressant-like and antistress effects from Melanotan II, including reversal of stress-induced anhedonia (loss of pleasure) ^[12].

Nerve repair. In rats, subcutaneous Melanotan II at 20 ug/kg every 48 hours improved recovery of sensory function after sciatic-nerve crush and partially protected against chemotherapy-induced neuropathy — while 2 and 50 ug/kg did nothing, a bell-shaped dose-response ^[7].

Social rescue in a disease model. In a maternal immune activation mouse model of autism, a Melanotan II course rescued social-behavior metrics — preclinical evidence that melanocortin activation can modify autism-relevant deficits ^[3].

Pigmentation and the melanotan 2 tanning record

The pigmentation evidence is real but small. In the pilot Phase I study, 3 healthy men received subcutaneous Melanotan II escalated from 0.01 to 0.025-0.03 mg/kg, dosed every other weekday for two weeks; facial, upper-body, and buttock pigmentation increased in 2 of 3 after only 5 low doses, alongside spontaneous erections and mild nausea ^[1]. These are study-design facts and not a dosing recommendation; Melanotan 2 has no approved human use.

The mechanism behind the melanotan 2 tanning effect: MC1R activation on melanocytes raises cAMP and drives the MITF-tyrosinase cascade, shifting pigment synthesis toward eumelanin (the darker, more protective melanin) — color without UV. A 2026 case report adds a cautionary note: reversible brown pigmentation of the oral mucosa in a man who self-injected 400 ug every other day for 64 days, with buccal pigment beginning to fade by 28 days after stopping while gingival pigment persisted at 3 months ^[31]. Pigmentation outlasts the peptide, because melanin synthesis continues downstream after the drug clears.

Appetite, metabolism, and the documented harms

Beyond the reward-center finding, central Melanotan II reduces food intake and body weight across rodent models and improves insulin sensitivity; intracerebroventricular dosing in diet-induced obese rats reduced intake and weight and improved insulin sensitivity beyond pair-fed controls ^[5]. Hindbrain melanocortin stimulation raised brown-fat and core temperature and heart rate via local sympathetic circuits ^[5].

The harms are equally documented. A nephrology case report and review attribute renal infarction to Melanotan II and note prior reports of rhabdomyolysis and renal failure ^[4]. Case reports document priapism ^[17][18], PRES ^[19], eruptive and dysplastic nevi ^[11][14], and melanoma ^[10][15]. Forensic analyses confirm that online product is frequently mislabeled and impure ^[22]. The honest summary: large, reproducible effects in rodents; a thin human record; and a real adverse-event signal in case reports.

Recent studies (2024-2026)

The record is still growing. A 2024 study showed melanocortin agonism activates the nucleus accumbens in a social context in an oxytocin-dependent manner — a mechanistic bridge between melanocortin signaling and social behavior ^[9]. A 2024 rat study reported antidepressant-like and antistress effects for Melanotan II under chronic unpredictable stress ^[12]. And a 2026 case report documented reversible oral-mucosal pigmentation after self-administration, one of the most recent published safety reports ^[31]. The neuro-behavioral stream is where the newest signal is.